Literature DB >> 7868955

Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy.

R H Gelber1, L P Murray, P Siu, M Tsang, T H Rea.   

Abstract

A clinical trial of minocycline in a total of 10 patients with previously untreated lepromatous leprosy was conducted in order to evaluate the efficacy of a single, initial, 200-mg dose and 100 mg twice daily of minocycline for a total duration of up to 3 months. Patients improved remarkably quickly. Although single-dose therapy did not result in a significant killing of Mycobacterium leprae, viable M. leprae were cleared from the dermis regularly by 3 months of twice-daily therapy, a rate similar to that achieved by minocycline 100 mg once daily. Because more side effects were noted herein than previously with 100 mg daily, we recommend that minocycline, when applied, be administered at 100 mg daily to leprosy patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868955

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  11 in total

1.  Another view of the therapy of leprosy.

Authors:  R H Gelber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.

Authors:  B Ji; S Sow; E Perani; C Lienhardt; V Diderot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.

Authors:  B Ji; P Jamet; E G Perani; S Sow; C Lienhardt; C Petinon; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

5.  Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.

Authors:  D K Banerjee; R D McDermott-Lancaster; S McKenzie
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers.

Authors:  M S Duthie; M N Hay; E M Rada; J Convit; L Ito; L K M Oyafuso; M I P Manini; I M B Goulart; J Lobato; L R Goulart; D Carter; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-05       Impact factor: 3.267

Review 7.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

8.  Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: A follow-up study.

Authors:  Raquel R Barbieri; Fernanda S N Manta; Suelen J M Moreira; Anna M Sales; José A C Nery; Lilian P R Nascimento; Mariana A Hacker; Antônio G Pacheco; Alice M Machado; Euzenir M Sarno; Milton O Moraes
Journal:  PLoS Negl Trop Dis       Date:  2019-03-05

9.  Nitazoxanide is active against Mycobacterium leprae.

Authors:  Mai Ann Bailey; Hana Na; Malcolm S Duthie; Thomas P Gillis; Ramanuj Lahiri; Tanya Parish
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

10.  An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Authors:  Liesbeth F Mieras; Anna T Taal; Wim H van Brakel; Emmanuelle Cambau; Paul R Saunderson; W Cairns S Smith; Cita Rosita S Prakoeswa; Linda Astari; David M Scollard; Dejair Caitano do Nascimento; Jacques Grosset; Hemanta K Kar; Shinzo Izumi; Laura Gillini; Marcos C L Virmond; Marieke G G Sturkenboom
Journal:  BMC Infect Dis       Date:  2018-10-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.